Attorney's Docket No.: 3800073.00002 / 911

MAR 1 2 2010

UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee : Vega et al. Serial No.: 10/022,249 Art Unit: 1631 Examiner: Jerry Lin

: December 17, 2001 Filed

Confirm. No.: 7196

Patent No.: 7,647,184

Cust. No. : 77202

Issued

: January 12, 2010

Title

: HIGH THROUGHPUT DIRECTED EVOLUTION BY RATIONAL

MUTAGENESIS

MAIL STOP OFFICE OF PETITIONS / OPLA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

APPLICATION FOR PATENT TERM ADJUSTMENT UNDER 37 C.F.R. § 1.705(D)

Dear Sir:

Patentee hereby files this Application for Patent Term Adjustment under 37 C.F.R. § 1.705(d), respectfully requesting reconsideration of the Patent Term Adjustment (PTA) accorded U.S. Patent No. 7,647,184 (the "'184 Patent"). The Determination of Patent Term Adjustment under 35 U.S.C. 154(b) included with the Issue Notification states that the Total Patent Term Adjustment at issuance is "0" days. Patentee hereby provides a statement of the facts involved, specifying the correct PTA, and the basis under 37 C.F.R. § 1.702 for the adjustment, the relevant dates for which the adjustment is sought, and the adjustment to which the patent is entitled.

03/16/2010 CCHAU2 00000086 021818 7647184

01 FC:1455 200.00 DA CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EM 315456112 US Date of Deposit: March 12, 2010

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Mail Stop Petitions, Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-

1450.

Stefanie Dost

Patentee: Vega et al.

Attorney's Docket No.: 3800073.00002 / 911

Patent No.: 7,647,184

Attorney's Docket No.: 3800073.00002 / 911

Request for Reconsideration of PTA

Issued: January 12, 2010

STATEMENT OF THE FACTS and REVIEW OF FILE HISTORY

As reflected in the file history, in good faith and candor, Patentee filed a *Letter Regarding Patent Term Adjustment at Allowance Pursuant to Comment 43 of the Final Rule* on September 24, 2009, which was granted November 18, 2009, thereby adjusting and increasing the APPL Delay by 100 days.

After Allowance, the Patent Office determined that a 10 day APPL delay should be made based on receipt of an *Information Disclosure Statement* on October 19, 2009, which was included in the filing of the issue fee payment. Patentee does not agree with this adjustment.

The subject Information Disclosure Statement entry was actually for copies of Supplemental Information Disclosure Statements that were previously filed before Allowance on February 07, 2008, July 10, 2008, and April 16, 2009, respectively, and referenced in the Comments on Reasons for Allowance filed with the Issue Fee Transmittal on October 19, 2009. As noted in the Comments on Reasons for Allowance, these Supplemental IDS's were mis-coded by the Patent Office, and not properly directed by the Office to Examiner Lin. Diligent exchanges with the Office to have the statements considered ultimately resulted in the submission of copies at that time for the convenience of the Examiner. (See Exhibit A.) Thus, there was no Applicant delay in submitting the Information Disclosure Statement.

Further, upon issuance of this '184 patent, the Patent Term Adjustment History and calculations were updated to include an entry on December 23, 2009 that recites "PTA 36 Months" with a zero total for USPTO Delay Days. <u>Patentee does not agree with this adjustment.</u>

In view of the <u>Wyeth v. Kappos</u> decision, Patentee respectfully submits that this calculation is incorrect and USPTO Delay days appear understated. This request is included in this application as the new PTO/SB/131 form "REQUEST FOR RECALCULATION OF PATENT TERM ADJUSTMENT IN VIEW OF WYETH" states use is for pre-Wyeth interpretation of 35 U.S.C. 154(b)(2)(A) only, and thus would not address the above stated APPL Delay calculation error.

Wyeth holds that a Patentee is entitled to all days beyond the prescribed limits for various actions and activities, as long as the days don't overlap. 35 U.S.C. §154(b)(1)(B) establishes that a patent's term is to be extended for each day that the application is pending beyond three years from the filing date. The three-year clock stops if certain events occur, such as the filing of a Request for Continued Examination (RCE). The PTA 36 month deadline for

Patentee: Vega et al.

Attorney's Docket No.: 3800073.00002 / 911

Patent No.: 7,647,184

Attorney's Docket No.: 3800073.00002 / 911

Request for Reconsideration of PTA

Issued: January 12, 2010

this application was December 17, 2004. A Request for Continued Examination was later filed September 01, 2005.

REMARKS

In summary and in consideration of the foregoing, Patentee respectfully requests correct of the calculation of the Total PTA, under provisions of 37 C.F.R. §1.705 and 35 U.S.C. §154 in view of <u>Wyeth</u>, to include the increase of **258 PTO Delay days** accumulated between the 36 month date of December 17, 2004, and the filing of the first *Request for Continued Examination* (RCE) on September 01, 2005, for a **total of 684 PTO Delay days** (426 + 258 = 684) minus the adjusted APPL Delay reduced from 460 to 450 days, for a **Total PTA of 234 days** instead of the "0" days currently accorded this patent. PTO Delay 684 minus APPL Delay 450 = 234.

The '184 Patent is not subject to a Terminal Disclaimer, and there were no circumstances constituting a failure to engage in reasonable efforts to conclude processing or examination of this application on the part of the Patentee.

In consideration of the nature of the error by the Office, Patentee respectfully requests the petition fee of \$200 required by 1.118(e) be waived.

If the \$200 fee is still required, please apply it and any other charges or credits in connection with the filing of this paper to Deposit Account No. 02-1818.

If there are any questions, please contact the undersigned. Thank you for your courtesy and consideration.

Respectfully submitted,

Stephanie Seidman

Reg. No. 33,779

Attorney Docket No. 3800073.00002 /911 Address all correspondence to: 77202

Stephanie Seidman K & L Gates LLP 3580 Carmel Mountain Rd, Ste 200 San Diego, CA 92130-6766

Telephone: (858) 509-7410 Facsimile: (858) 509-7466

email: stephanie.seidman@klgates.com

Patentee : Vega et al.

Patent No.: 7,647,184

: January 12, 2010

Attorney's Docket No.: 3800073.00002 / 911

Request for Reconsideration of PTA

Exhibit A

Date Stamped postcard of October 19, 2009 listing copies of subject Supplemental Information Disclosure Statements

Copies of Supplemental Information Disclosure Statements included with Comments on Reasons for Allowance filed Octobver 19, 2009:

February 07. 2008 July 10, 2008 April 16, 2009

		-
EM 315455117 US	Customer Copy Label 11:F: April 2004 EXPRESS MAIL UNITED STATES POSTAL SERVICES POST Office To Addressee	1
RIGIN (POSTAL SERVICE USE ONLY) ZIP Code Day of Delivery Postage Next 270 270 Del Dep \$	DELIVERY (POSTAL USE ONLY) Delivery Attempt Mo. Day Delivery Attempt Time AN Mo. Day	
Scheduled Date of Delivery Return Receipt Fee te Accepted Month Day Scheduled Tirrie of Delivery COD Fee Insurance Fee	Delivery Attempt Time An Imployee Signature Mo. Day Time Carta Noed Signature	0
Total Postage & Fees	Mio Day: PM WAVEROPSIGNATURE/point weikington/y/Add Traus Solar Ground waverond opening to consider wished points of control to the control of	.(
inti Alpha Country Code Acceptance Emp. Initials STOMER USE ONLY	Registrative of the first transfer of the fi	Ű
HOD OF PAYMENT: X920230 ess Mail Corporate Acct. (No.5) 858 509 7400 ROM: (PLEASE PRINT) PHONE	Federal Agency Acct. No. or	¥2
SL GATES SSC CARMEL MOUNTAIN RD STE 200 SAN DIEGO CA 92130-6766	MAIL STOP ISSUE FEE COMMISSIONER FOR PATENTS PO BOX 1450	Ú
	ALEXANDRÍA VA 22313-1450	(
38000731		55

Call 1-800-222-1811

Attorney's Docket No. / 3800073-00002 / 91 I	Express Mail Label No. EM 315455117 US	Mailing Date October 19, 2009	For PTO Use Only Do Not Mark in This Area
Application No. 10/022,249	Filing Date December 17, 2001	Attorney/Secretary Init	· , · · ·
Title of the Invention HIGH THROUGHPU MUTAGENESIS Applicant Manuel Vega et al.	T DIRECTED EVOLUTIO	ON BY RATIONAL	ONE TREE
Enclosures Transmittal I Comments R Comments R (3 pgs) with a Disclosure Sta JUL 10, 2008 PTOL-85 Par and Advance C Deposit Accord	Letter and fee authorization (esponsive to the Reasons for Entity Status and Informattached copies of three (3) Suptements date stamped APR 1 (3 pgs), and FEB 07, 2008 (5 the B-Fee(s) Transmittal for IOrder for 14 copies (1page an ant); and	Allowance and Additional tion Disclosure Statements pplemental Information 6, 2009 (3 pgs), 5 pgs) (ssue Fee, Publication Fee,	OCT 1 9 2009 BY

FOR PICKUP OR TRACKING: Visit WWW.USPS.COM

** Attachment to Comments on Reasons for Allowance: Copy of Information Disclosure Statement, filed April 16, 2009 ** Attorney's Docket No.: 0119365-00002 / 911

NITED STATES PATENT AND TRADEMARK OFFICE

Manuel Vega et al. Applicant

Art Unit : 1631

Serial No.:

10/022,249 December 17, 2001 Examiner: Jerry Lin Conf. No.: 7196

Filed Cust. No.

77202

Title

HIGH THROUGHPUT DIRECTED EVOLUTION BY RATIONAL

MUTAGENESIS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§1.97-1.98

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed after the receipt of a First Office Action on the Merits for the above-captioned application, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 02-1818.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and copies of the cited non U.S. patent documents are provided herewith in connection with the above-captioned application.

The documents listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

A copy of a Communication from the European Patent Office (Document I), issued April 14, 2008, in connection with corresponding European Patent Application No. 02798018.4 regarding the intention to grant an European patent is provided. A copy of an Office Action,

CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EM 315453677 US Date of Deposit April 16, 2009.

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR Postal "Express Mail Post Office to Addressee Service under 37 Cf. §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office P.O. Box 1450, Alexandria, VA, 22313-1450.

Applicant: Manuel Vega et al.

Serial No.: 10/022,249 : December 17, 2001

Filed

Supplemental Information Disclosure Statement

(Document II), issued September 16, 2008, in connection with co-owned U.S. Application Ser. No. 10/658,355 is provided. A Copy of an Office Action, (Document III), issued December 24, 2008, in connection with co-owned U.S. Application Ser. No. 11/707,014 is provided. The table below lists Documents I-III and includes a column that provides a space next to the documents to be considered, for the Examiner's initials.

Examiner Initial	Document No.	Document
	I	Copy of Communication from European Patent Office, issued April 14, 2008, in connection with corresponding European Patent Application No. 02798018.4
	II	Copy of Office Action, issued September 16, 2008, in connection with U.S. Application Ser. No. 10/658,355
•	III	Copy of Office Action, issued December 24, 2008, in connection with U.S. Application Ser. No. 11/707,014

In the Office Actions, dated May 13, 2008 and October 16, 2008, the Examiner indicated that the Information Disclosure Statements (IDSs) submitted on February 7, 2008 and July 10, 2008, were considered and initialed by the Examiner. The IDS filed on February 7, 2008 contained a Table listing Office Actions and European Examination Reports cited in related and corresponding U.S. and foreign Patent Applications. The IDS filed on July 10, 2008 contained a Table listing an International Search Report cited in a related foreign Patent Application. These tables were not initialed by the Examiner. These IDSs included the application number of the application in which the IDS was being submitted, a column that provides a blank space next to each citation for the Examiner's initials, a heading on the listing that clearly indicates the list is an Information Disclosure Statement, and copies of listed documents. Therefore, the February 7, 2008 and July 10, 2008 IDSs are in compliance with 37 CFR §§ 1.97, 1.98 and MPEP § 609 and Applicant respectfully requests that Examiner consider and initial all information listed in the tables submitted in the IDSs filed February 7, 2008 and July 10, 2008.

Further to the list provided in the communication filed on July 10, 2008, applicant also makes known to the examiner the following pending U.S. and International Applications that have one or more common inventors and/or are common ownership:

** Attachment to Comments on Reasons for Allowance: Copy of Information Disclosure Statement, filed April 16, 2009 ** Attorney's Docket No.: 119365-00002 / 911

Supplemental Information Disclosure Statement

Applicant: Manuel Vega et al. Serial No.: 10/022,249

Filed : December 17, 2001

U.S.S.N.	Filing Date	Publ. No.	Publ. Date	Docket No.
11/704,141	02/07/07	2008-0194477	08/14/08	922D
11/706,088	02/13/07	2008-0274081	11/06/08	922F
11/788,836	04/19/07	2008-0260820	10/23/08	932
12/082,365	04/09/08	2008-0274081	11/06/08	9221
12/082,389	04/09/08	2009-0053147	02/26/09	922J
Int'l App. No.	Filing Date	Publ No.	Publ. Date	Docket No.
PCT/GB07/004520	11/27/2007	WO 08/065372	06/05/08	931PC

Although these documents and applications are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97 (g and h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56 (b) exists.

Applicant respectfully requests that the Examiner review the foregoing documents and make them of record in the file history of the above-captioned application.

Respectful submitted,

Stephanie Seidman Reg. No. 35, 179

Attorney Docket No. 0119365-00002 / 911
Address all correspondence to:
Stephanie Seidman
K&L Gates LLP
3580 Carmel Mountain Road, Suite 200
San Diego, California 92130

Telephone: (858) 509-7410 Facsimile: (858) 509-7460

email: stephanie.seidman@klgates.com

<u>Attachment 2:</u> Copy of Information Disclosure Statement, filed July 10, 2008, in U.S. Application Serial No. 10/022,249



** Attachment to Comments on Reasons for Allowance: Copy of Information Disclosure Statement, filed July 10, 2008 ** Attorney's Docket No.: 119365-000027 911

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Manuel Vega et al.

Art Unit : 1631

Serial No.: 10/022,249

Examiner: Jerry Lin

Filed

: December 17, 2001

Conf. No.: 7196

Cust. No.

77202

Title

HIGH THROUGHPUT DIRECTED EVOLUTION BY RATIONAL

MUTAGENESIS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§1.97-1.98

Dear Sir:

This Supplemental Information Disclosure Statement is filed after a Request for Continued Examination of the above-captioned application and prior to receipt of an Office Action. Thus, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 02-1818.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and copies of the cited non U.S. patent documents are provided herewith in connection with the above-captioned application.

The documents listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

> CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EM 247737964 US Date of Deposit July 10, 2008 I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Applicant: Manuel Vega et al. Serial No.: 10/022,249 Filed: December 17, 2001

A Copy of an International Search Report, (Document I), issued June 13, 2008, in connection with co-owned International Application No. PCT/US2007/014219 is provided. The table below lists Documents I and includes a column that provides a space next to the documents to be considered, for the Examiner's initials.

Examiner Initial	Document No.	Document
	I	Copy of International Search Report, issued June 13, 2008, in connection with co-owned International Application No. PCT/US2007/014219

In the International Search Report, (Document I), issued June 13, 2008, the following document is cited: Chang et al., "Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis. Residues Asn(89)-Gly(93) are critical for binding factor VIIIa." *J Biol Chem* 277:25393-25399 (2002). Document 1 is made of record in the instant application in this Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents.

In the Office Action dated May 13, 2008, the Examiner indicated that the Information Disclosure Statement (IDS) submitted on February 7, 2008 was considered and initialed by the Examiner. The IDS filed on February 7, 2008 contained a Table listing Office Actions and European Examination Reports cited in related and corresponding U.S. and foreign Patent Applications. This Table was not initialed by the Examiner. The Information Disclosure Statement includes the serial number of the application for which the IDS was submitted, a heading that clearly indicates the list is an Information Disclosure Statement, a Table containing a column with a blank space next to each citation for the Examiner's initials and copies of cited documents. Therefore, the February 7, 2008 IDS is in compliance with 37 CFR §§ 1.97, 1.98 and MPEP § 609. Applicant respectfully requests that the Examiner consider and initial all information listed in the Table submitted in the IDS filed February 7, 2008.

Further to the list provided in the Information Disclosure Statement filed on February 7, 2008, Applicant also makes known to the Examiner the following pending U.S. and International Applications that have one or more common inventors and/ or are commonly owned:

** Attachment to Comments on Reasons for Allowance: Copy of Information Disclosure Statement, filed July 10, 2008 **
Attorney's Docket No.: 119365-00002 / 911

Serial No.: 10/022,249

Filed

Applicant: Manuel Vega et al.

: December 17, 2001

Supplemental Information Disclosure Statement

U.S.S.N.	Filing Date	Publ. No.	Publ. Date	Docket No.
11/703,610	02/06/07	2008-0075672	03/27/08	922C
11/729,267	03/27/07	2008-0038224	02/14/08	924
11/729,266	03/27/07	2008-0003202	01/03/08	924B
11/818.985	06/15/07	2008-0102115	05/01/08	930
11/825,604	07/05/07	2008-0159977	07/03/08	922H
11/998,387	11/28/07	n/a	n/a	931
12/082,365	04/09/08	n/a	n/a	922I
12/082,389	04/09/08	n/a	n/a	922J
12/157,150	06/06/08	n/a	n/a	922K
Int'l App. No.	Filing Date	Publ No.	Publ. Date	Docket No.
PCT/GB07/004520	11/27/2007	n/a	n/a	931PC

Although these documents and applications are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97 (g and h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56 (b) exists.

Applicant respectfully requests that the Examiner review the foregoing documents and make them of record in the file history of the above-captioned application.

Respectfully/submitted,

Stephanie Seidman Reg. No. 33,779

Attorney Docket No. 119365-00002 / 911 Address all correspondence to:

Stephanie Seidman

Bell, Boyd & Lloyd LLP

3580 Carmel Mountain Road, Suite 200

San Diego, California 92130 Telephone: (858) 509-7410 Facsimile: (858) 509-7460

email: sseidman@bellboyd.com

<u>Attachment 3:</u> Copy of Information Disclosure Statement, filed February 7, 2008, in U.S. Application Serial No. 10/022,249



Attorney's Docket No.: 17109-002001 / 911

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Manuel Vega et al. Art Unit : 1631 Examiner: Jerry Lin Serial No.: 10/022,249 Conf. No.: 7196 : December 17, 2001 Filed

20985 Cust. No. :

: HIGH THROUGHPUT DIRECTED EVOLUTION BY RATIONAL Title

MUTAGENESIS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§1.97-1.98

Dear Sir:

Because this Supplemental Information Disclosure Statement is after receipt of a first Office Action on the Merits of the above-captioned application, the filing fee of \$180 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and copies of the cited non U.S. patent documents are provided herewith in connection with the above-captioned application.

00000070 10022249 02/12/2008 CCHAU1

01 FC:1806

180.00 DP

CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EV 965985825 US Date of Deposit February 7, 2008 I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Traderpark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman

Applicant: Manuel Vega et al. Serial No.: 10/022,249

Filed: December 17, 2001

Attorney's Docket No.: 17109-002001 / 911 Supplemental Information Disclosure Statement

The documents listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed item is necessary.

A copy of a European Examination Report (Document I), issued July 31, 2007, in connection with corresponding European Patent Application No. 02798018.4 is provided. Copies of three U.S. Office Actions (Documents II, III and IV), issued May 9, 2006, March 12, 2007, and December 10, 2007, respectively, in connection with co-owned U.S. Application Ser. No. 10/658,355 are provided. Copies of two European Examination Reports (Documents V and VI), issued August 2, 2005 and June 2, 2006, respectively, in connection with European Patent Application No. 03748392.2 are provided. European Patent Application No. 03748392.2 corresponds to U.S. Application Ser. No. 10/658,355. The table below lists Documents I-VI and includes a column that provides a space next to the documents to be considered, for the Examiner's initials.

Examiner Document Initial No.		Document		
	I	Copy of European Examination Report, issued July 31, 2007, in connection with European Patent Application No. 02798018.4		
	II	Copy of U.S. Office Action, issued May 9, 2006, in connection with U.S. Application Ser. No. 10/658,355		
	nı	Copy of U.S. Office Action, issued March 12, 2007, in connection with U.S. Application Ser. No. 10/658,355		
	īV	Copy of U.S. Office Action, issued December 10, 2007, in connection with U.S. Application Ser. No. 10/658,355		
, , , , , , , , , , , , , , , , , , ,	v	Copy of European Examination Report, issued August 2, 2005, in connection with European Patent Application No. 03748392.2		
	VI	Copy of European Examination Report, issued June 2, 2006, in connection with European Patent Application No. 03748392.2		

In the U.S. Office Action, issued May 9, 2006 (Document II), three documents are cited:

1) US 5,096,815, 2) Alam et al., "Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro," J. Biochem. 65:183-190 (1998), and 3) Chiang et al., "In vivo genetic analysis of bacterial virulence," Ann. Rev. Microbiology 53:129-154 (1999). Documents 1-3 are made of record in

Applicant: Manuel Vega et al. Serial No.: 10/022,249

: December 17, 2001 Filed

Attorney's Docket No.: 17109-002001 / 911 Supplemental Information Disclosure Statement

the instant application in an Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents, filed June 22, 2006. In the U.S. Office Action, issued March 12, 2007 (Document III), one document is cited: 1) Stabach et al., "Sitedirected mutagenesis of alpha II spectrin at codon 1175 modulates its mu-calpain susceptibility," Biochemistry 36:57-65 (1997). Document 1 is made of record in the instant application in this Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents. In the U.S. Office Action, issued December 10, 2007 (Document IV), four documents are cited: 1) US 6,548,640, 2) Jones et al., "The rapid generation of mutation data matrics from protein sequences" CABIOS 8:275-282 (1992), 3) Alam et al., "Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro," J. Biochem. 65:183-190 (1998), and 4) Chiang et al., "In vivo genetic analysis of bacterial virulence," Ann. Rev. Microbiology 53:129-154 (1999). Documents 1-2 are made of record in the instant application in this Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents. Documents 3-4 are made of record in the instant application in an Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents, filed June 22, 2006.

In the European Examination Report, issued August 2, 2005 (Document V), five documents are cited: 1) US 5,223,409, 2) WO 01/61344, 3) Manetti et al., "Design and realization of a tailor-made enzyme to modify the molecular recognition of 2-arylpropionic esters by Candida rugosa lipase," Biochem. Biophys. Acta. 1543(1):146-158 (2000), 4) WO 03/023032 5) Lewerenz et al., "Shared receptor components but distinct complexes for alpha and beta interferons," J. Mol. Biol. 282(3):585-599 (1998). Documents 1-5 are made of record in the instant application in an Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents, filed March 15, 2005. In the European Examination Report, issued June 2, 2006 (Document VI), three documents are cited: 1) US 6,013,478, 2) WO 95/23813, 3) WO 01/32844. Documents 1-3 are made of record in the instant application in an Information Disclosure Statement, supplied with Forms PTO-1449 and copies of the cited non U.S. patent documents, filed March 15, 2005.

Applicant: Manuel Vega et al.

Serial No.: 10/022,249 Filed: December 17, 2001 Attorney's Docket No.: 17109-002001 / 911 Supplemental Information Disclosure Statement

Further to the list provided in the communication filed on March 2, 2007, applicant also makes known to the examiner the following pending U.S. and International Applications that have one or more common inventors and/ or are commonly owned:

U.S.S.N.	Filing Date	Publication or Issue No.	Publication or Issue Date	Docket No.
11/267,871	11/03/05	2007-0249532	10/25/07	925
11/656,921	01/22/07	2007-0254838	11/01/07	922E
11/703,610	02/06/07	n/a	n/a	922C
11/704,141	02/07/07	n/a	n/a	922D
11/706,088	02/13/07	2007-0172459	07/26/07	922F
11/707,014	02/14/07	2007-0224665	09/27/07	922G
11/729,267	03/27/07	n/a	n/a	924
11/729,266	03/27/07	n/a	n/a	924B
11/788,836	04/19/07	n/a	n/a	932
11/818,985	06/15/07	n/a	n/a	930
11/825,604	07/05/07	n/a	n/a	922H
Int'l App. No.	Filing Date	Publication No.	Publication Date	Docket No.
PCT/IB06/002034	05/04/06	WO 06/120580	11/16/06	926PC
PCT/EP07/002700	03/27/07	WO 07/110231	10/04/07	924PC
PCT/US07/14219	06/15/07	n/a	n/a	930PC
			<u> </u>	

Although these documents and applications are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97 (g and h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56 (b) exists.

Applicant respectfully requests that the Examiner review the foregoing documents and make them of record in the file history of the above-captioned application.

** Attachment to Comments on Reasons for Allowance: Copy of Information Disclosure Statement, filed February 7, 2008 **

Applicant: Manuel Vega et al. Serial No.: 10/022,249

: December 17, 2001 Filed

Attorney's Docket No.: 17109-002001 / 911 Supplemental Information Disclosure Statement

Respectfully submitted,

Stephanie Seidman Reg. No. 33,779

Attorney Docket No. 17109-002001 / 911 Address all correspondence to: Stephanie Seidman Fish & Richardson P.C. 12390 El Camino Real San Diego, California 92130 Telephone: (858) 678-4777 Facsimile: (202) 626-7796 email: seidman@fr.com